IO Biotech (IOBT) Competitors

Phathom Pharmaceuticals (NASDAQ:PHAT) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Which has better earnings and valuation, PHAT or IOBT?

IO Biotech has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$55.25M	13.33	-$334.33M	-$4.73	-2.19
IO Biotech	N/A	N/A	-$95.49M	-$1.49	-0.88

Do analysts prefer PHAT or IOBT?

Phathom Pharmaceuticals currently has a consensus price target of $17.50, suggesting a potential upside of 68.59%. IO Biotech has a consensus price target of $8.67, suggesting a potential upside of 561.58%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts plainly believe IO Biotech is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media prefer PHAT or IOBT?

In the previous week, IO Biotech had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 16 mentions for IO Biotech and 14 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.08 beat IO Biotech's score of -0.07 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IO Biotech	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Which has more volatility & risk, PHAT or IOBT?

Phathom Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Is PHAT or IOBT more profitable?

IO Biotech has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-289.51%	N/A	-90.40%
IO Biotech	N/A	-162.55%	-125.08%

Do insiders and institutionals have more ownership in PHAT or IOBT?

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats IO Biotech on 8 of the 15 factors compared between the two stocks.